Evidence map›Paper›PMID 33602892›Full record

ArticleBlood cancer journal2021

Upregulation of AXL and β-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance.

Sutapa Sinha, Charla R Secreto, Justin C Boysen, Connie Lesnick, Zhiquan Wang, Wei Ding, Timothy G Call, Saad J Kenderian, Sameer A Parikh, Steven L Warner and 3 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sutapa SinhaDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Charla R SecretoDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Justin C BoysenDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Connie LesnickDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Zhiquan WangDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-8243-7251
Wei DingDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-9811-4601
Timothy G CallDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Saad J KenderianDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-2767-3830
Sameer A ParikhDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-3221-7314
Steven L WarnerTolero Pharmaceuticals, Inc., Lehi, UT, USA.
David J BearssTolero Pharmaceuticals, Inc., Lehi, UT, USA.
Asish K GhoshStephenson Cancer Center and Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Neil E KayDivision of Hematology, Mayo Clinic, Rochester, MN, USA. kay.neil@mayo.edu.ORCID 0000-0002-5951-5055

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug Resistance, NeoplasmUp-RegulationAntineoplastic AgentsAxl Receptor Tyrosine Kinasebeta CateninCell Line, TumorCells, CulturedCoculture TechniquesHumansLeukemia, Lymphocytic, Chronic, B-CellMesenchymal Stem CellsProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesAntineoplastic AgentsAXL protein, humanAxl Receptor Tyrosine Kinasebeta CateninCTNNB1 protein, humanProto-Oncogene ProteinsReceptor Protein-Tyrosine Kinases

Identifiers

PMID33602892
PMCPMC7893033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.